河托伐他汀对不稳定型心绞痛患者血清hs—CRP和血脂水平的影响

目的观察阿托伐他汀治疗不稳定型心绞痛（UAP）的临床疗效，探讨其对UAP患者血清hs—CRP和血脂水平的影响。方法将48例已确诊的UAP患者随机分为观察组和对照组，每组24例，对照组采用常规内科治疗，观察组在常规治疗的基础上加用阿托伐他汀治疗。用药3个月后比较其疗效、血清hs—CRP水平及血脂水平的变化情况。结果观察组的总有效率为87．50％，明显高于对照组（58．33％），差异有统计学意义（P〈0．05）；血清hs—CRP水平及血脂水平均较治疗前明显改善，且观察组优于对照组，差异有统计学意义（P〈0．05）。结论阿托伐他汀可提高UAP的疗效，显著降低hs—CRP水平，具有较强的调脂作用，是用于治疗UAP较理想的药物之一，值得临床广泛推广应用。

Effect of Atorvastatin on patients with unstable angina pectoris serum hs-CRP and blood lipid levels

Objective To observe the clinical curative effect of Atorvastatin in treatment for unstable angina pectoris(UAP),and discuss the effects of atorvastatin on serum UAP in patients with hs-CRP and blood lipid levels.Methods Forty-eight patients with UAP were randomly divided into observation group and control group,twenty-four cases in each group,the control group was treated by conventional internal medicine treatment,and the observation group was treated by Atorvastatin based on the conventional treatment.The curative effect,serum hs-CRP and blood lipid levels changes were compared after three months later.Results In the observation group,the total efficiency rate was 87.50%,it was significantly higher than the control group(58.33%),the difference was statistically significant(P < 0.05);the level of serum hs-CRP and blood lipid levels were significantly improved than before the treatment,and the observation group was better than the control group,the difference was statistically significant(P < 0.05).Conclusion Atorvastatin can improve the effect of UAP,significantly reduce the hs-CRP level and has strong effect of lipid lowering,it is an ideal drug for UAP,and be worth widely application in clinic.